The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study.
Guilherme Piovezani RamosChristina DimopoulosNicholas M McDonaldLaurens P JanssensKenneth W HungDeborah ProctorElizabeth RuggieroSunanda KaneDavid H BruiningWilliam A FaubionLaura E RaffalsEdward V LoftusBadr Al-BawardyPublished in: Inflammatory bowel diseases (2022)
Almost one-third of patients had worsening EIMs after VDZ, which resulted in VDZ discontinuation in approximately 10% of patients. Previous biologic use or concurrent immunosuppressant or corticosteroid therapy did not predict EIM course after VDZ.